Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 1]
Phase 1 dose-escalation and dose-expansion study to evaluate the safety of Azer-cel (PBCAR0191) in relapsed/refractory non-Hodgkin lymphoma …
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL [Phase 1]
Phase 1 trial evaluating EBV-specific cytotoxic T lymphocytes for advanced B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia has …
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Expanded Access to Venetoclax
Expanded access to venetoclax is being offered for multiple hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, A…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [Phase 3]
Phase 3 trial comparing Pirtobrutinib plus Venetoclax and Rituximab (PVR) versus Venetoclax and Rituximab (VR) in previously treated chronic…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]
Phase 1/2 study evaluating the safety, pharmacokinetics, and efficacy of the combination of tafasitamab and parsaclisib in relapsed/refracto…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax [Phase 2]
Phase 2 clinical trial evaluating minimal residual disease assessment by next-generation sequencing to minimize exposure in patients with ch…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy [Phase 3]
Phase 3 clinical trial evaluating a digital health intervention for self-management and telemonitoring in CAR-T therapy is currently recruit…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial results update for GDC-0199 (venetoclax) in combination with obinutuzumab and ibrutinib in relapsed/refractory or previously…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial of the oral BTK inhibitor LOXO-305 (pirtobrutinib) in patients with previously treated chronic lymphocy…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) [Phase 2]
A Phase 2 trial evaluating the combination of lenalidomide and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma is curre…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluates PRT2527 as a standalone therapy and in combination with zanubrutinib or venetoclax for relapsed/refractor…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
A Phase 3 clinical trial comparing pirtobrutinib to bendamustine plus rituximab in untreated chronic lymphocytic leukemia/small lymphocytic …
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Clinical trial update describing a Bristol-Myers Squibb-sponsored study to perform transgene assay testing on tumor samples from patients wh…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab [Phase 2]
Phase 2 study evaluating disease risk mutation-guided finite acalabrutinib plus venetoclax for relapsed chronic lymphocytic leukemia and sma…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: CLL Therapy Approaches in Russia
AstraZeneca-sponsored clinical trial activity for Chronic Lymphocytic Leukemia in Russia is listed as ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial investigating a fixed-duration regimen of pirtobrutinib plus obinutuzumab in chronic lymphocytic leukemia or small lymphocyt…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]
Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 clinical trial update for ABBV-319 evaluating adverse events, change in disease activity, and pharmacokinetics in adults with relaps…
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL [Phase 3]
A Phase 3 global trial (ROCKET-CLL) comparing rocbrutinib to pirtobrutinib in patients previously treated with covalent BTK inhibitors and w…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies [Phase 1]
A Phase 1 clinical trial update for a bicistronic CAR-T cell therapy targeting CD19 and CD20 in B-cell malignancies; current status is not r…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
This clinical trial investigates reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B-cell lympho…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies [Phase 1]
A Phase 1 clinical trial evaluating UB-VV111 with and without rapamycin for relapsed/refractory CD19+ B-cell malignancies is currently recru…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 1]
Phase 1 trial update of ABBV-453 in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, focusing on adverse eve…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL [Phase 3]
A Phase 3 trial is evaluating adding Sonrotoclax to Zanubrutinib for patients with previously untreated chronic lymphocytic leukemia or smal…